FAKTOR OPTIONSSCHEIN - NOVO-NORDISK B | Delayed Deutsche Boerse AG 10:21:02 2024-06-14 am EDT | ||
| 558 EUR | +4.67% |
|
| Current month | +28.72% | ||
| 1 month | +40.78% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 558 | +4.67% |
| 24-06-13 | 533.1 | -3.70% |
| 24-06-12 | 553.6 | +3.04% |
| 24-06-11 | 537.2 | -1.45% |
| 24-06-10 | 545.1 | -0.17% |
Delayed Quote Deutsche Boerse AG
Last update June 14, 2024 at 10:21 am EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| WKN | PF5NND |
| ISIN | DE000PF5NND4 |
| Date issued | 2019-06-27 |
| Strike | 979.7 kr |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 4.69 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 567 € |
|---|---|
| Lowest since issue | 2.75 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
979.7
DKK
Average target price
934.3
DKK
Spread / Average Target
-4.64%
- Stock Market
- Certificates
- Certificat
